These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30928951)

  • 1. Methodological advantages and disadvantages of parallel and crossover randomised clinical trials on methylphenidate for attention deficit hyperactivity disorder: a systematic review and meta-analyses.
    Krogh HB; Storebø OJ; Faltinsen E; Todorovac A; Ydedahl-Jensen E; Magnusson FL; Holmskov M; Gerner T; Gluud C; Simonsen E
    BMJ Open; 2019 Mar; 9(3):e026478. PubMed ID: 30928951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Ramstad E; Krogh HB; Nilausen TD; Skoog M; Holmskov M; Rosendal S; Groth C; Magnusson FL; Moreira-Maia CR; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD009885. PubMed ID: 26599576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
    Storebø OJ; Storm MRO; Pereira Ribeiro J; Skoog M; Groth C; Callesen HE; Schaug JP; Darling Rasmussen P; Huus CL; Zwi M; Kirubakaran R; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD009885. PubMed ID: 36971690
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methylphenidate for attention-deficit/hyperactivity disorder in children and adolescents: Cochrane systematic review with meta-analyses and trial sequential analyses of randomised clinical trials.
    Storebø OJ; Krogh HB; Ramstad E; Moreira-Maia CR; Holmskov M; Skoog M; Nilausen TD; Magnusson FL; Zwi M; Gillies D; Rosendal S; Groth C; Rasmussen KB; Gauci D; Kirubakaran R; Forsbøl B; Simonsen E; Gluud C
    BMJ; 2015 Nov; 351():h5203. PubMed ID: 26608309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methylphenidate for children and adolescents with autism spectrum disorder.
    Sturman N; Deckx L; van Driel ML
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD011144. PubMed ID: 29159857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Boesen K; Paludan-Müller AS; Gøtzsche PC; Jørgensen KJ
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD012857. PubMed ID: 35201607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Cândido RCF; Menezes de Padua CA; Golder S; Junqueira DR
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013011. PubMed ID: 33460048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.
    Epstein T; Patsopoulos NA; Weiser M
    Cochrane Database Syst Rev; 2014 Sep; (9):CD005041. PubMed ID: 25230710
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological treatment for attention deficit hyperactivity disorder (ADHD) in children with comorbid tic disorders.
    Osland ST; Steeves TD; Pringsheim T
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD007990. PubMed ID: 29944175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Randomized, Double-Blind, Placebo-Controlled, Two-Way Crossover Clinical Trial of ORADUR-Methylphenidate for Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Huang YS; Yeh CB; Chen CH; Shang CY; Gau SS
    J Child Adolesc Psychopharmacol; 2021 Apr; 31(3):164-178. PubMed ID: 33395356
    [No Abstract]   [Full Text] [Related]  

  • 12. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials.
    Catalá-López F; Hutton B; Núñez-Beltrán A; Page MJ; Ridao M; Macías Saint-Gerons D; Catalá MA; Tabarés-Seisdedos R; Moher D
    PLoS One; 2017; 12(7):e0180355. PubMed ID: 28700715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH; Nagy P; Childress AC; Frick G; Yan B; Pliszka S
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gastrointestinal adverse events during methylphenidate treatment of children and adolescents with attention deficit hyperactivity disorder: A systematic review with meta-analysis and Trial Sequential Analysis of randomised clinical trials.
    Holmskov M; Storebø OJ; Moreira-Maia CR; Ramstad E; Magnusson FL; Krogh HB; Groth C; Gillies D; Zwi M; Skoog M; Gluud C; Simonsen E
    PLoS One; 2017; 12(6):e0178187. PubMed ID: 28617801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimizing adverse events while maintaining clinical improvement in a pediatric attention-deficit/hyperactivity disorder crossover trial with dextroamphetamine and methylphenidate.
    Ramtvedt BE; Aabech HS; Sundet K
    J Child Adolesc Psychopharmacol; 2014 Apr; 24(3):130-9. PubMed ID: 24666268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylphenidate combined with aripiprazole in children and adolescents with bipolar disorder and attention-deficit/hyperactivity disorder: a randomized crossover trial.
    Zeni CP; Tramontina S; Ketzer CR; Pheula GF; Rohde LA
    J Child Adolesc Psychopharmacol; 2009 Oct; 19(5):553-61. PubMed ID: 19877980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized crossover clinical study showing that methylphenidate-SODAS improves attention-deficit/hyperactivity disorder symptoms in adolescents with substance use disorder.
    Szobot CM; Rohde LA; Katz B; Ruaro P; Schaefer T; Walcher M; Bukstein O; Pechansky F
    Braz J Med Biol Res; 2008 Mar; 41(3):250-7. PubMed ID: 18327433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/hyperactivity disorder: results of a double-blind, placebo-controlled crossover study.
    Jain U; Hechtman L; Weiss M; Ahmed TS; Reiz JL; Donnelly GA; Harsanyi Z; Darke AC
    J Clin Psychiatry; 2007 Feb; 68(2):268-77. PubMed ID: 17335326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.
    Adler LA; Zimmerman B; Starr HL; Silber S; Palumbo J; Orman C; Spencer T
    J Clin Psychopharmacol; 2009 Jun; 29(3):239-47. PubMed ID: 19440077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.